tradingkey.logo

BRIEF-Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia

ReutersFeb 13, 2025 2:29 PM

- Moleculin Biotech Inc MBRX.O:

  • MOLECULIN RECEIVES POSITIVE FDA GUIDANCE FOR ACCELERATION OF ITS REGISTRATION-ENABLING MIRACLE TRIAL FOR R/R ACUTE MYELOID LEUKEMIA (AML)

  • MOLECULIN BIOTECH INC - FDA ALLOWS REDUCTION IN SIZE OF MOLECULIN'S PHASE 3 TRIAL

  • MOLECULIN BIOTECH INC - AMENDED PROTOCOL ALLOWS UNBLINDING OF DATA AT 45 SUBJECTS

  • MOLECULIN BIOTECH INC - FIRST UNBLINDING EXPECTED IN SECOND HALF OF 2025

Source text: ID:nPn1DNcZga

Further company coverage: MBRX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI